rs41275750
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001626.6(AKT2):c.*1684G>C variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.112 in 233,642 control chromosomes in the GnomAD database, including 2,315 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.13 ( 1896 hom., cov: 32)
Exomes 𝑓: 0.085 ( 419 hom. )
Consequence
AKT2
NM_001626.6 3_prime_UTR
NM_001626.6 3_prime_UTR
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.0570
Publications
10 publications found
Genes affected
AKT2 (HGNC:392): (AKT serine/threonine kinase 2) This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains, which is involved in signaling pathways. The gene serves as an oncogene in the tumorigenesis of cancer cells For example, its overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins, and has also been implicated in insulin signaling. [provided by RefSeq, Nov 2019]
AKT2 Gene-Disease associations (from GenCC):
- hypoinsulinemic hypoglycemia and body hemihypertrophyInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P
- diabetes mellitus, noninsulin-dependentInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- AKT2-related familial partial lipodystrophyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- type 2 diabetes mellitusInheritance: AD Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.77).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.269 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| AKT2 | NM_001626.6 | c.*1684G>C | 3_prime_UTR_variant | Exon 14 of 14 | ENST00000392038.7 | NP_001617.1 | ||
| AKT2 | NM_001330511.1 | c.*1684G>C | 3_prime_UTR_variant | Exon 12 of 12 | NP_001317440.1 | |||
| AKT2 | NM_001243027.3 | c.*1684G>C | 3_prime_UTR_variant | Exon 14 of 14 | NP_001229956.1 | |||
| AKT2 | NM_001243028.3 | c.*1684G>C | 3_prime_UTR_variant | Exon 13 of 13 | NP_001229957.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| AKT2 | ENST00000392038.7 | c.*1684G>C | 3_prime_UTR_variant | Exon 14 of 14 | 1 | NM_001626.6 | ENSP00000375892.2 | |||
| AKT2 | ENST00000424901.5 | c.*1684G>C | 3_prime_UTR_variant | Exon 13 of 13 | 5 | ENSP00000399532.2 | ||||
| AKT2 | ENST00000476266.5 | n.*149G>C | downstream_gene_variant | 5 | ||||||
| AKT2 | ENST00000483166.5 | n.*147G>C | downstream_gene_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.127 AC: 19270AN: 151898Hom.: 1892 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
19270
AN:
151898
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.0850 AC: 6939AN: 81628Hom.: 419 Cov.: 0 AF XY: 0.0840 AC XY: 3164AN XY: 37650 show subpopulations
GnomAD4 exome
AF:
AC:
6939
AN:
81628
Hom.:
Cov.:
0
AF XY:
AC XY:
3164
AN XY:
37650
show subpopulations
African (AFR)
AF:
AC:
1135
AN:
3904
American (AMR)
AF:
AC:
194
AN:
2502
Ashkenazi Jewish (ASJ)
AF:
AC:
386
AN:
5124
East Asian (EAS)
AF:
AC:
671
AN:
11410
South Asian (SAS)
AF:
AC:
53
AN:
710
European-Finnish (FIN)
AF:
AC:
23
AN:
470
Middle Eastern (MID)
AF:
AC:
68
AN:
498
European-Non Finnish (NFE)
AF:
AC:
3783
AN:
50228
Other (OTH)
AF:
AC:
626
AN:
6782
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.483
Heterozygous variant carriers
0
364
728
1091
1455
1819
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.127 AC: 19286AN: 152014Hom.: 1896 Cov.: 32 AF XY: 0.125 AC XY: 9253AN XY: 74300 show subpopulations
GnomAD4 genome
AF:
AC:
19286
AN:
152014
Hom.:
Cov.:
32
AF XY:
AC XY:
9253
AN XY:
74300
show subpopulations
African (AFR)
AF:
AC:
11294
AN:
41414
American (AMR)
AF:
AC:
1166
AN:
15276
Ashkenazi Jewish (ASJ)
AF:
AC:
271
AN:
3464
East Asian (EAS)
AF:
AC:
272
AN:
5138
South Asian (SAS)
AF:
AC:
312
AN:
4806
European-Finnish (FIN)
AF:
AC:
572
AN:
10612
Middle Eastern (MID)
AF:
AC:
38
AN:
294
European-Non Finnish (NFE)
AF:
AC:
5028
AN:
67990
Other (OTH)
AF:
AC:
248
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
778
1556
2333
3111
3889
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
194
388
582
776
970
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
266
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.